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Abstract
Background: Alternating ibuprofen and acetaminophen for the treatment of febrile children is a
prevalent practice among physicians and parents, despite the lack of evidence on effectiveness or
safety. This randomized, double-blind and placebo-controlled clinical trial aims at comparing the
antipyretic effectiveness and safety of a single administration of alternating ibuprofen and
acetaminophen doses to that of ibuprofen mono-therapy in febrile children.
Methods: Seventy febrile children were randomly allocated to receive either a single oral dose of
10 mg/kg ibuprofen and 15 mg/kg oral acetaminophen after 4 hours, or a similar dose of ibuprofen
and placebo at 4 hours. Rectal temperature was measured at baseline, 4, 5, 6, 7 and 8 hours later.
Endpoints included proportions of afebrile children at 6, 7 and 8 hours, maximum decline in
temperature, time to recurrence of fever, and change in temperature from baseline at each time
point. Intent-to-treat analysis was planned with statistical significance set at P < 0.05.
Results: A higher proportion of subjects in the intervention group (83.3%) became afebrile at 6
hours than in the control group (57.6%); P = 0.018. This difference was accentuated at 7 and 8
hours (P < 0.001) with a significantly longer time to recurrence of fever in the intervention group
(mean ± SD of 7.4 ± 1.3 versus 5.7 ± 2.2 hours), P < 0.001. Odds ratios (95%CI) for defervescence
were 5.6 (1.3; 23.8), 19.5 (3.5; 108.9) and 15.3 (3.4; 68.3) at 6, 7 and 8 hours respectively. Two-way
ANOVA with repeated measures over time revealed a significantly larger decline in temperature
in the intervention group at times 7 (P = 0.026) and 8 (P = 0.002) hours.
Conclusion: A single dose of alternating ibuprofen and acetaminophen appears to be a superior
antipyretic regimen than ibuprofen mono-therapy. Further studies are needed to confirm these
findings.
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Background
Fever, a beneficial immune host response [1], is often a
cause of significant anxiety among parents of febrile chil-
dren. Fever phobia [2], which refers to unproven concerns
about fever causing serious harm, is widely prevalent
among caregivers [2,3], and may lead to abuse of antipy-
retics with subsequent risk of toxicity. Acetaminophen
and ibuprofen are the most commonly used antipyretics
in pediatrics. These two drugs have well-established effi-
cacy and safety profiles, when used in appropriate dosages
[4,5]. Recently, however, we have observed the emergence
and increasing popularity of a new antipyretic regimen in
Lebanon that combines acetaminophen and ibuprofen in
alternating doses. This practice has also been reported
from America and Europe [6-9]. The new trend of com-
bining ibuprofen and acetaminophen for treating fever
has not been studied in clinical trials for efficacy or safety.
In fact, several investigators have raised concerns that such
combinations may result in significant adverse effects on
the liver or the kidney [7-9]. Specifically, the risk of renal
toxicity may increase when both drugs are used together,
since ibuprofen reduces glutathione and, in the presence
of increased concentrations of acetaminophen in the kid-
ney and reduced glutathione, can lead to renal tubular
necrosis [7-9].
In view of the present popularity of the combined alter-
nating ibuprofen and acetaminophen treatment of febrile
children, the potential risks associated with it, and the
absence of scientific evidence on its safety or superior
effectiveness to mono-therapy, we elected to conduct this
randomized controlled trial that aims at comparing the
effectiveness and safety of a single administration of com-
bined alternating ibuprofen and acetaminophen doses to
that of ibuprofen mono-therapy. We chose to investigate
the antipyretic effectiveness and safety of a single dose of
each regimen, rather than multiple doses, because we
believed it would be unethical to expose our subjects to
possible harm from multiple doses prior to having scien-
tific evidence of single-dose effectiveness.
Methods
Setting
This study was conducted between November 2002 and
April 2005, in the paediatric inpatient services of two hos-
pitals in Beirut: the American University of Beirut Medical
Centre (AUBMC), which is a tertiary care facility; and Naj-
jar Hospital, a secondary care facility. The study was
approved by the Institutional Review Board and the Ethics
Committee of the American University of Beirut, as well as
the Board of Najjar Hospital.
Subjects
Eligible subjects were febrile inpatients aged between 6
months and 14 years, whose rectal temperature was ≥
38.8°C. Exclusion criteria included any of the following
conditions: vomiting, any medical or surgical condition
that precluded oral drug administration, acute or chronic
hepatic disease, malabsorption syndromes, acute or
chronic renal disease with the exception of urinary tract
infection, chronic metabolic disease, bleeding disorders,
asthma, chronic neurological disease that may affect cen-
tral thermoregulation, cancer, immune suppression, sep-
sis, critical medical status, or known allergy to
acetaminophen or ibuprofen. Children with concurrent
or previous intake of antibiotics were not excluded if still
febrile at the time of interview. All antipyretics were
stopped for 8 hours prior to the initiation of the study.
Study design
This was a randomized, double-blind and placebo-con-
trolled clinical trial in which subjects were randomly allo-
cated into one of two treatment groups: an intervention
group where a single oral dose of 10 mg/kg ibuprofen was
administered at baseline followed by a single oral dose of
15 mg/kg acetaminophen four hours later; and a control
group where a similar dose of ibuprofen was administered
initially, followed by placebo four hours later. The alloca-
tion sequence was generated by one of the co-investiga-
tors (HT) who was not involved in subject recruitment,
drug administration or outcome assessment. The admin-
istration of acetaminophen or placebo four hours after
baseline was chosen to coincide with the expected time of
maximum antipyresis of ibuprofen, after which there is
gradual waning of this effect. Hence, we anticipated that
the antipyretic action of acetaminophen may result in fur-
ther control of the temperature between 4 and 8 hours
from baseline.
Study procedure
After obtaining the approval of the treating physician, the
parent(s) of the eligible child was/were approached for
interview and enrolment. During the interview, a trained
research assistant who was responsible for subject enrol-
ment administered a structured questionnaire designed to
collect information on the following variables: gender;
date of birth; maternal and paternal levels of education;
maternal and paternal jobs; fever duration; diagnosis; pre-
vious or concurrent antibiotic intake; previous antipyretic
intake; previous use of ibuprofen and acetaminophen in
alternating schedule; the person who recommended the
alternating antipyretic regimen; parental rating of the
alternating antipyretic regimen effectiveness. The purpose
and procedure of the trial were fully explained to the fam-
ily, and written parental consent was obtained, together
with the assent of the subject if older than ten years. Chil-
dren enrolled in the study were then assigned a random
number by the hospital pharmacist according to a compu-
ter-generated random-number list, which was kept with
the pharmacist until the end of the study. The pharmacistBMC Medicine 2006, 4:4 http://www.biomedcentral.com/1741-7015/4/4
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Flow diagram of the subjects' progress through the study Figure 1
Flow diagram of the subjects' progress through the study.
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who prepared all study medications was thus un-blinded
to the treatment allocation of subjects, while subjects, par-
ents, research assistant, nurses responsible for drug
administration and outcome assessment, treating physi-
cians, data analyst (co-investigator ZM) and remaining
investigators were all blinded to the patients' assignment.
Baseline rectal temperature was recorded using a portable
thermistor with single-use disposable probe covers (Sure
Temp 679, Welch Allyn). The same thermometer was used
for the whole duration of the study. Rectal temperatures
were subsequently recorded by the nurse in charge of the
subject's care at 4, 5, 6, 7 and 8 hours from baseline.
Study medications
The drugs used in this study, ibuprofen, acetaminophen
and its placebo, were supplied by Julphar (Gulf Pharma-
ceutical Industries, United Arab Emirates). The oral ibu-
profen used was a 100 mg/5 ml suspension (Profinal,
Julphar), while oral acetaminophen was a 250 mg /5 ml
suspension (Adol, Julphar) and its placebo was a suspen-
sion with similar colour and exipient to Adol.
Statistical analyses
The primary outcome of the study was the proportion of
children with normal body temperature at 6 hours. Nor-
mal temperature was defined as a rectal measurement
ranging between 36.5°C and 37.9°C. We hypothesized
that 50% of febrile subjects who receive ibuprofen and
placebo will drop their rectal temperature to <38.0°C at 6
hours, and that 80% of subjects in the combination anti-
pyretic group will become afebrile at 6 hours. To detect
this 30% difference in the proportions of afebrile subjects,
with α of 0.05, β of 20% and a 2-tailed test for the differ-
ence in proportions, a sample size of 90 subjects is
needed: 45 in each group. Additional outcomes included:
proportions of afebrile children in each group at 7 and 8
hours from baseline; maximum decline in temperature
during the study period; time to recurrence of fever; the
mean temperature changes from baseline at t = 4, 5, 6, 7
and 8 hours; the proportion of patients in each group with
any adverse effect that may be related to either drug such
as hypothermia, chilliness or gastrointestinal bleeding.
Statistical analyses were performed using SPSS, version
12.0. We investigated the association between categorical
variables and treatment groups with Pearson's Chi Square
test, and the relationship between continuous variables
and treatment groups with Student's t-test. Data were also
analyzed using two-way ANOVA with repeated measures
over time. Error terms were modeled as having a covari-
ance structure of the first-order autoregressive type. In
order to eliminate bias that could be caused by baseline
temperature, the variable chosen for analysis was the
change in temperature, from baseline, at times t (t = 4, 5,
6, 7, 8). Additional testing with logistic regression was
performed to investigate the association between the pro-
portion of afebrile subjects at 6 hours as the dependent
variable and the treatment group as the independent var-
iable, adjusting for temperature at 4 hours, previous anti-
biotic intake and previous antipyretic intake. Similar
regression analyses were used to test the associations
between the same predictors and the proportions of afe-
brile subjects at 7 and 8 hours as dependent variables.
Odds ratios with 95% confidence intervals were calcu-
lated. Intent-to-treat analysis was planned with statistical
significance set at P < 0.05.
Results
Baseline characteristics
Between November 2002 and April 2005, 143 parents
were approached for interview and questionnaire admin-
istration. Of these, 55 (38.5%) admitted having used ibu-
profen and acetaminophen on alternating basis, of whom
84.3% initiated this practice following a physician's
advice while in 13.7% it was self-initiated. The practice
was rated as being very effective in treating high fever by
71.7% of parents who used the regimen.
Figure 1 summarizes the progress of these subjects
through the study, which was terminated after two and a
half years owing to a very slow recruitment rate. The final
sample size enrolled was 70 subjects, randomized either
to the ibuprofen and acetaminophen combination treat-
ment group (37) or the ibuprofen and placebo group
(33). One patient from the intervention group withdrew
consent at 4 hours and could not be included in the final
analysis because the parents refused temperature moni-
toring. Two patients from the control group withdrew
consent at 6 hours; they were kept for the intent to treat
analysis at 6 hours, but no temperature recordings were
obtained at 7 and 8 hours.
Except for gender and the type of father's job, baseline
characteristics were not significantly different between
those who were enrolled in the study and those who
refused. There was a higher proportion of males among
enrolled subjects (64.3%) as compared to non-enrolled
(47.9%), P = 0.049. In addition, 83.3% of fathers with a
manual job consented to the study, in contrast to fathers
with administrative or academic jobs (46.0%), P = 0.045.
As for the randomized subjects (70), the overall mean
(SD) age was 3.7 (3.1) years, with an age range of 6
months-12.8 years. The mean (SD) duration of fever was
4.7 (4.1) days, with a range of 1.0–30.0 days. One patient
had a prolonged fever of 30 days that was later diagnosed
as due to tuberculosis. Those enrolled included 45
(64.3%) males and 45 (67.2%) subjects receiving anti-
biotic treatment. The characteristics of the two groups areBMC Medicine 2006, 4:4 http://www.biomedcentral.com/1741-7015/4/4
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shown in Table 1. There were no significant differences
between the two treatment groups with respect to gender,
age, underlying basic disease causing fever, duration of
fever, previous antipyretic use, concurrent antibiotic
administration, mean baseline temperature (39.3 ±
0.5°C) or mean temperature at 4 hours (37.5 ± 0.7 °C), at
the time of acetaminophen/placebo administration
(Table 1). In addition, there were no differences in the
treatment allocation of the patients recruited from
AUBMC (32) and those recruited from Najjar Hospital
(38).
Primary and secondary outcomes
A significantly larger number of subjects in the interven-
tion group (30/36; 83.3%) achieved a normal body tem-
perature at 6 hours than in the control group (19/33;
57.6%), P = 0.018. This difference persisted at 7 and 8
hours with significantly higher proportions of afebrile
subjects in the combined antipyretic group (31/36; 86.1%
versus 14/31; 45.2% at 7 hours, and 29/36; 80.6% versus
11/31; 35.5% at 8 hours; P < 0.001 at both times) (Table
2). In univariate logistic regression testing, temperature at
4 hours was found to be a significant predictor of the anti-
pyretic response at 6, 7, and 8 hours (P ≤ 0.001), whereas
previous antibiotic or antipyretic intakes were not. The
logistic regression model revealed that subjects in the
intervention group were significantly more likely than
those in the control group to become afebrile at 6, 7 and
8 hours: OR (95% CI) of 5.6 (1.3; 23.8) at 6 hours; 19.5
(3.5; 108.9) at 7 hours; and 15.3 (3.4; 68.3) at 8 hours,.
The two groups had similar maximum decline in temper-
ature (mean ± SD of 2.2 ± 0.7°C in the intervention group
versus 2.1 ± 1.2°C in the control group; P = 0.8). How-
ever, the combined antipyretic group had a significantly
longer duration of antipyresis than the control group,
with the mean (SD) times to recurrence of fever being 7.4
(1.3) hours versus 5.7 (2.3) hours, respectively; P < 0.001
(Table 2). Two-way ANOVA with repeated measures over
time revealed a significant interaction between time and
treatment group (P = 0.011), hence the change in temper-
ature followed different trends in the two treatment
Table 1: Subjects' baseline characteristics.
Total (N = 70) Combined ibuprofen
& acetaminophen (N = 37)
Ibuprofen (N = 33) P value
Male gender N (%) 45 (64.3) 26 (70.3) 19 (57.6) 0.3
Age (years)
Mean (SD) 3.7 (3.1) 3.7 (3.3) 3.6 (2.9) 0.9
Range 0.5–12.8
Illness duration (Days)
Mean (SD) 4.7 (4.1) 4.6 (4.9) 4.7 (2.9) 0.9
Range 1–30 1–30 1–14
Fever aetiology N (%)
Viral 44 (62.9) 26 (70.3) 18 (54.5)
Bacterial 19 (27.1) 8(21.6) 11 (33.3) 0.4
Other 7 (10.0) 3 (8.1) 4 (12.1)
Hospital N (%)
AUBMC 32 (45.7) 16 (43.2) 16 (48.5) 0.7
Najjar 38 (54.3) 21 (56.8) 17 (51.5)
Previous antipyretic N (%) 68 (98.6) 37 (100) 31 (96.9) 0.3
Antibiotic intake N (%) 45 (67.2) 22 (59.5) 23 (76.7) 0.1
Baseline temperature (°C)
Mean (SD) 39.3 (0.5) 39.3 (0.5) 39.4 (0.6) 0.3
Temperature at 4 hours (°C)
Mean (SD) 37.5 (0.7) 37.5 (0.7) 37.7 (0.9) 0.3
Table 2: Comparison of primary and secondary outcomes in both treatment groups.
Combined Ibuprofen & 
acetaminophen N = 36
Ibuprofen N = 33 P value
Afebrile at 6 hours N (%) 30 (83.3) 19 (57.6) 0.018
Afebrile at 7 hours N (%) 31 (86.1) 14 (45.2) <0.001
Afebrile at 8 hours N (%) 29 (80.6) 11 (35.5) <0.001
Maximum temperature 
decline Mean (SD)
2.2 (0.7) 2.1 (1.2) 0.793BMC Medicine 2006, 4:4 http://www.biomedcentral.com/1741-7015/4/4
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groups. This is well demonstrated when the change in
temperature is plotted against time, as shown in Figure 2.
Owing to this significant interaction, comparison of the
two groups at each time period was performed with Bon-
ferroni adjustments revealing significant differences, with
the intervention group showing larger declines in temper-
ature than the control group at times 7 and 8 hours (P =
0.026 and 0.002, respectively).
As for the side effects of medications, low body tempera-
ture (defined as a rectal temperature below 36.5°C)
occurred in 11 (15.9%) of the subjects: 5 (13.9%) in the
combined antipyretic group and 6 (18.2%) in the control
group (P = 0.6). The temperature range of these episodes
was between 35.0°C and 36.2°C. No serious adverse reac-
tions were observed in these subjects. In addition, none of
the subjects developed any symptom or sign suggestive of
gastrointestinal, hepatic or renal toxicity.
Discussion
Alternating antipyretics is becoming a popular practice
among physicians caring for febrile children. Mayoral et
al. [6] reported that 50% of physicians surveyed in the
United States advised parents to alternate ibuprofen with
acetaminophen, despite the absence of any scientific evi-
dence to support the effectiveness or safety of this practice.
Younger physicians are more likely to alternate antipyret-
ics, reflecting their anxiety about parental fever phobia
[6,9]. Alternating antipyretics is not unique to physicians
in the United States but has been reported from other
countries as well [9]. It is being widely practiced in our
country, as evident from the fact that more than one third
of parents interviewed in this study had alternated aceta-
minophen and ibuprofen previously. This practice was
based on physician's advice in 84.3% and was self-initi-
ated in 13.7% of our families, emphasizing the popularity
of this regimen. However, combined antipyretic treatment
can be dangerous and may precipitate hepatic or renal tox-
icities due to glutathione pathway impairment, especially
in the sick, dehydrated or fasting child [6-8,10-14]. Dos-
ing errors due to confusing dosing schedules may increase
the risk of overdose of one or both drugs, with resultant
grave consequences.
Our results suggest that a single administration of alter-
nating ibuprofen and acetaminophen doses is a more
effective antipyretic regimen than ibuprofen and placebo.
A significantly higher proportion of subjects in the com-
bined regimen became afebrile compared to those treated
with ibuprofen alone. This antipyretic effect was main-
tained for an additional two hours in the intervention
group, as evidenced by the significantly higher propor-
tions of afebrile subjects at 7 and 8 hours from baseline.
Subjects in the intervention group had a longer duration
of antipyresis that persisted throughout the study. In addi-
tion, they had larger reductions in their body tempera-
tures at 7 and 8 hours from baseline.
Strengths and limitations
This study is the first clinical trial to investigate whether
the combined alternating antipyretic regimen is more
effective than ibuprofen mono-therapy. Although our
results suggest the superiority of the combined alternating
regimen, our findings need to be confirmed in larger tri-
als, since we were forced to stop the trial before achieving
our calculated sample size. This was because of obstacles
faced during recruitment that were primarily related to
parental anxiety regarding children's participation in
research, and to physicians' reluctance to permit enrol-
ment of their patients in a clinical trial. Such obstacles
have been encountered by many investigators and have
been previously reported in the pediatric research litera-
ture [15]. Based on the available sample size, and the dif-
ference between proportions of afebrile subjects obtained
in our results, we recalculated the actual power of the
study and found it to be 66% at 6 hours, 92% at 7 hours
and 95% at 8 hours, with α = 0.05.
Subjects included in this study were inpatients who are
presumed to be sicker than outpatients; hence the validity
of generalizing the findings to outpatients may be in ques-
tion. However, both ibuprofen and acetaminophen are
used in similar dosages and at similar intervals in inpa-
tients as well as outpatients, irrespective of the severity of
the primary disease. In addition, the antipyretic response
associated with either drug does not correlate with the dis-
ease being viral or bacterial. Therefore we believe that the
findings of this study may apply to hospitalized and out-
patient febrile children alike.
Since the outcome of interest in this study was "effective-
ness" rather than "efficacy", we did not exclude subjects
Mean (SE) change in temperature, from baseline, over time in  the two treatment groups Figure 2
Mean (SE) change in temperature, from baseline, over time in 
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receiving antibiotics from enrolment, or subjects with
prior intake of antipyretics. However, antipyretics were
stopped for 8 hours prior to enrolment, the time at which
a febrile subject may receive antipyretic treatment in "real
clinical life". It may be argued that the antipyretic effects
of the drugs investigated are confounded by antibiotic
administration and previous antipyretic intake. However,
since this was a randomized clinical trial, we anticipated
that the randomization process would dilute these effects
by distributing the subjects equally among the two treat-
ment groups. Indeed, the proportions of subjects receiv-
ing antibiotics and those with prior antipyretic intake
were not significantly different between the two groups,
suggesting adequate randomization. In addition, and
since the desired sample size was not achieved, we
adjusted for antibiotic and antipyretic intakes in the logis-
tic regression model, which revealed both variables to be
insignificant predictors of the antipyretic response at 6, 7,
and 8 hours.
Implications for practice
Despite the effectiveness of the combined antipyretic reg-
imen shown in this study, we emphasize that our findings
should not be used as a justification for advising this prac-
tice. The duration of our study was a short 8 hour interval,
during which a single dose of ibuprofen and acetami-
nophen was administered. Although no renal, hepatic or
gastrointestinal adverse effects were observed, no definite
conclusions on the safety of the combined antipyretic
treatment can be made before larger multi-dose clinical
trials are conducted demonstrating its safety. In addition,
the antipyretic advantage of the combined antipyretics
may be attenuated with multiple dosing of ibuprofen and
acetaminophen, and become comparable to repeated ibu-
profen mono-therapy. A similar situation has been
reported by Walson et al. [16], where multi-dose treat-
ments with 2.5 mg/kg and 5 mg/kg ibuprofen for 24–48
hours resulted in equivalent antipyresis to 10 mg/kg ibu-
profen or 15 mg/kg acetaminophen, after the second dose
and continuing to 24–48 hours later.
Conclusion
A single administration of alternating ibuprofen and
acetaminophen doses to febrile children appears to be a
more effective antipyretic than ibuprofen alone. It is our
position, however, that combined treatment should not
be used in clinical practice before larger clinical trials con-
firm the safety and effectiveness of this regimen.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MMN prepared grant submission in relation to this study,
contributed to the design, data acquisition, analysis and
interpretation, drafting, revision and final approval of the
manuscript. HT contributed to the design, data analysis
and interpretation, drafting, revision and final approval of
the manuscript. ZM contributed to statistical analysis,
revision and final approval of the manuscript. MI contrib-
uted to data acquisition, analysis, drafting and final
approval of the manuscript. RS participated in grant sub-
mission, design, revision and final approval of the manu-
script. FC contributed substantially to data acquisition,
drafting and final approval. MM participated in grant sub-
mission, drafting, revision and final approval of the man-
uscript.
Additional material
Acknowledgements
This study was funded by the Medical Practice Plan of the Faculty of Medi-
cine at the American University of Beirut, Grant number 686056. We are 
grateful to all the pediatric nurses at the American University of Beirut 
Medical Center and Najjar Hospital for their enthusiastic and dedicated 
work that made this study possible. We also thank the following physicians 
for approving the enrolment of their patients in the study: from AUBMC, 
Drs. Fadi Bitar, Youssef Comair, Ibrahim Dabbous, Ghassan Dbaibo, Nabil 
Kanaan, Suheil Lakkis, Salman Mroueh, Salim Musallam, Samar Muwakkit, 
Mounir Obeid, Hiba Osman, Bassem Saab, Said Saghieh, Sami Sanjad, Nabil 
Shararah, Jinan Usta, and Khaled Yunis; from Najjar Hospital, Drs. Bassam 
Abou Merhi, Lama Abyad, Mohamad-Bilal Arab, Iman Awada, Nada Bukhari, 
Zuheir Fleifel, Mirvat Hemadeh, Afif Kabbani, Ziad Naja, Youssef Safawi, 
Mohamad Shebbo, Zafer Shehadeh, Maha Shouman, Mohannad Tafankaji, 
Ikram Tannir and Bilan Yaman. We are grateful to Dr. Samer Jabbour for 
his help in the design of the study, to Julphar (Gulf Pharmaceutical Indus-
tries, United Arab Emirates) for their generous donation of all the drugs 
investigated, and to Miss Huda Dagher, our research assistant, whose ded-
ication and enthusiasm made this study possible.
References
1. Kluger MJ, Kozak W, Conn CA, Leon LR, Soszynski D: The adaptive
value of fever.  Inf Dis Clinics North America 1996, 10:1-20.
2. Schmitt BD: Fever phobia. Misconceptions of parents about
fever.  AJDC 1980, 134:176-181.
3. Crocetti M, Moghbeli N, Serwint J: Fever phobia revisited: have
parental misconceptions about fever changed in 20 years?
Pediatrics 2001, 107:1241-1246.
4. Lesko SM, Mitchell AA: The safety of acetaminophen and ibu-
profen among children younger than two years old.  Pediatrics
1999, 104(4):e39.
5. Perrott DA, Piira T, Goodenough B, Champion GD: Efficacy and
safety of acetaminophen vs ibuprofen for treating children's
pain or fever. A meta-analysis.  Arch Pediatr Adolsc Med 2004,
158:521-526.
Additional File 1
CONSORT checklist: BMC Consort.doc
Click here for file
[http://www.biomedcentral.com/content/supplementary/1741-
7015-4-4-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2006, 4:4 http://www.biomedcentral.com/1741-7015/4/4
Page 8 of 8
(page number not for citation purposes)
6. Mayoral CE, Marino RV, Rosenfeld W, Greensher J: Alternating
antipyretics: Is this an alternative?  Pediatrics 2000,
105:1009-1012.
7. Rosefsky JB: Alternating antipyretics: is this an alternative?
Pediatrics 2001, 108:1236-1237.
8. Del Vecchio MT, Sundel ER: Alternating antipyretics: is this an
alternative?  Pediatrics 2001, 108:1236-1237.
9. Diez Domingo J, Burgos Ramirez A, Garrido Garcia J, Ballester Sanz
A, Moreno Carretero E: Use of alternating antipyretics in the
treatment of fever in Spain.  An Esp Pediatr 2001, 55:503-510.
10. Block S: Ibuprofen and/or acetaminophen: what price for
'euthermia'?  J Ped 1997, 131:332-333.
11. Mofenson H, Caraccio T, McFee R, Greensher J: Combined antipy-
retic therapy: another potential source of chronic acetami-
nophen toxicity.  J Ped 1998, 133:712-714.
12. Carson SM: Alternating acetaminophen and ibuprofen in the
febrile child: examination of the evidence regarding efficacy
and safety.  Pediatr Nurs 2003, 29:379-382.
13. Heubi JE, Barbacci MB, Zimmerman HJ: Therapeutic misdaven-
tures with acetaminophen: Hepatotoxixity after multiple
doses in children.  J Ped 1998, 132:22-27.
14. American Academy of Pediatrics: Committee on Drugs: Acetami-
nophen toxicity in children.  Pediatrics 2001, 108:1020-1024.
15. Caldwell PHY, Butow PN, Craig JC: Parents' attitudes to chil-
dren's participation in randomized controlled trials.  J Ped
2003, 142:554-559.
16. Walson PD, Galletta G, Chomilo F, Braden NJ, Sawyer LA, Schein-
baum ML: Comparison of multidose ibuprofen and acetami-
nophen therapy in febrile children.  AJDC 1992, 146:626-632.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/4/4/prepub